Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA Donut Hole Pledge Sets Nice Tone, But Negotiations Continue On $80 Bil. Contribution

This article was originally published in The Pink Sheet Daily

Executive Summary

Higher drug rebates to Medicaid, Medicare under discussion, as are savings from follow-on biologics.

You may also be interested in...



Getting To $80 Bil.: PhRMA Expects Mix Of Rebates And Fees In Finance Bill

The Pharmaceutical Research and Manufacturers of America is expecting to make good on its pledge to contribute $80 billion to health care reform through a combination of drug rebates and fees, in addition to savings from follow-on biologics and the previously announced 50 percent discount on drugs used in the Medicare Part D donut hole

Getting To $80 Bil.: PhRMA Expects Mix Of Rebates And Fees In Finance Bill

The Pharmaceutical Research and Manufacturers of America is expecting to make good on its pledge to contribute $80 billion to health care reform through a combination of drug rebates and fees, in addition to savings from follow-on biologics and the previously announced 50 percent discount on drugs used in the Medicare Part D donut hole

Getting To $80 Bil.: PhRMA Expects Mix Of Drug Rebates And Fees In Senate Finance Bill

In addition to the announced discount for drugs in the Part D donut hole, PhRMA anticipates the Senate Finance Committee's bipartisan bill will seek rebates and fees from pharmaceutical manufacturers.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069595

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel